TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Reduction in infection risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: TMT-A and TMT-B score differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAS‐28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SI reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion rate of the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Attendance at exercise training sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: work-days lost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: recurrent appendicitis rate
Endpoint domain: Adverse events/effects
Primary endpoint: Collateral flow via the posterior communicating artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Diameter of the anterior communicating artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: plasma t‐PA antigen concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: plasma t‐PA activity concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Utilization of palliative care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Antibody production by B-lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of nocturia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of LNs dissected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discovery rate of LN metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean mHHS score at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion achieving outcome score >=74 at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion achieving MCID of more than 8 points at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hPFS (hazard progression-free survival)
Endpoint domain: Mortality/survival
Primary endpoint: oPFS (overall progression-free survival)
Endpoint domain: Mortality/survival
Primary endpoint: hOR (hazard objective response)
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in cognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to perform the TGUG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization rate of hepatic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBV DNA seroconversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBeAg/HBeAb seroconversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life related to getting out of the house
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Proper inhaler technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of complete sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence to activity recommendations
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Diagnostic accuracy for minor pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: noncephalic presentation at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Reduction in WOMAC scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in VAS scores for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fetal loss
Endpoint domain: Adverse events/effects
Primary endpoint: nocturnal oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Odds of death or disability
Endpoint domain: Adverse events/effects
Primary endpoint: improved pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total hemoglobin mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Suicidal ideation on ISST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BHS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Up-regulation of immune activation markers HLA-DR and CD38
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase of the CD4+ central memory population
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidence of withdrawal or vocalization with venepuncture
Endpoint domain: Adverse events/effects
Primary endpoint: pain rating of venepuncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTFJ fibular contacting area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: medial tibial cartilage volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knee radiographic and MRI-based OA-related structural abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of all-cause death and cardiovascular hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Pain level during needle insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain level during anesthetic delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SOFA scores at day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed gastric emptying incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bone Mineral Density (BMD) at ultradistal radius
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: survival rate of prostheses
Endpoint domain: Mortality/survival
Primary endpoint: clinicians' impressions of sit-to-stand change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of presumptive enterovirus infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of viral enteritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Serum levels of IFN‐γ
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anxiety improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: NFL thickness reproducibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optic nerve head parameters reproducibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of brodalumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rates at 4w and 8w
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity as a screening tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with pVL below 200 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients with pVL below 20 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gain in CD4 cells/mm3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Trueness of scanners
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Precision of scanners
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reference scanner file estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung cancer-specific survival
Endpoint domain: Mortality/survival
Primary endpoint: Mean rate of change in myopic direction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean refractive change at age 5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean refractive error at age 5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TIMI major and minor bleeding rates
Endpoint domain: Adverse events/effects
Primary endpoint: Response of 75% improvement in PASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroprotective titers for hepatitis B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroprotective titers to H. influenzae type b
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rise in serum antirotavirus immunoglobulin A levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: QALD benefit
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in relative weight category (BMI group)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in LDL size and particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: soluble intercellular adhesion molecule‐1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: soluble vascular cell adhesion molecule‐1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: E‐selectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reproducibility of IOP measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical failure at 6 months after successful PTCA
Endpoint domain: Mortality/survival
Primary endpoint: Retention of BP measurement skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dermal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: 5-year disease overall survival (DOS)
Endpoint domain: Mortality/survival
Primary endpoint: Leg fat percent change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with clinical lipodystrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-infinity) of 5'-DFUR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) of 5'-DFUR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients presenting normal stools
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of patients achieving study endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary calcium, serum phosphate, and calcium × phosphate product levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful insertion of TDT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Successful stent placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Effective Dose (ED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of micturition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Median anti-HBs antibody titre
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Median CD40s titre
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean number of new Gd+ MRI lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Pain-free rates 2 hours postdose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease of the average spinal pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase of the quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Adequate analgesia for planned surgical intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Motor block completeness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average conjunctival autograft thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative discomfort
Endpoint domain: Adverse events/effects
Primary endpoint: Seattle Angina Questionnaire summary score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analogue score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: functional internal rotation (IR) of the hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Survey completion rates
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Rate of wound complications
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of respiratory complications
Endpoint domain: Adverse events/effects
Primary endpoint: Postprandial epigastric fullness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Low-Density Lipoprotein cholesterol (LDL-c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Responder rate for back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder rate for leg pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of back pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAS28(ESR) LDA at week 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: X-ray fluoroscopy times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Low back pain score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of long-acting pharmacologic treatment for ADHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of T vaginalis infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of persistent urethritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seminal plasma HIV RNA concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: COP sway path length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mediolateral mean velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anteroposterior mean velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of lymphomas
Endpoint domain: Mortality/survival
Primary endpoint: Change in EBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: healthcare utilization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: degree of steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: influx of leukocytes into inflamed joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Amplitude of transient torsion during saccades
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: lower extremity motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: achieved weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: linear growth rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: regurgitation or vomiting after supplementation
Endpoint domain: Adverse events/effects
Primary endpoint: Mean clearance (CL) of ropivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) of 3-OH-ropivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary excretion of PPX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of painful symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction with functional capacity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: satisfaction with psychological health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: satisfaction with financial situation
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: current night dry cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Severity of daytime heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of reflux episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Language performance (Aachen Aphasia Test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost after 12 months
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Target attainment for HDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Target attainment for total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Target attainment for LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Palmar tilt angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gartland-Werley score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: mean liver retinol reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bioavailability of lansoprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maximum plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived ability to reduce risks of a heart attack
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy as evaluated by the modified Rankin Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 h glucose iAUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24 h mean amplitude of glycaemic excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 10 h fat oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hand hygiene adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BII (BPH Impact Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IPSS Q8 (International Prostate Symptom Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Personal and social performance
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Increase in FRC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Recurrent stroke and TIA cases
Endpoint domain: Mortality/survival
Primary endpoint: Accumulation of anti-FXa activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRS during-movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRC shoulder flexion and extension strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Postinstrumentation pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: parent-reported child behavior problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: parenting confidence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: parental stress
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: postoperative gastrointestinal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of HIV-1 infection at 9 months
Endpoint domain: Mortality/survival
Primary endpoint: Correlation between markers of inflammation and antioxidant capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: employability
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Nasal obstruction/congestion (NO/C) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bilateral polyp grade (BPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ethmoid sinus obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in lumbar pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes